CN Patent

CN102579417B — Hdac抑制剂的药物制剂

Assigned to Topotarget UK Ltd · Expires 2014-11-26 · 11y expired

What this patent protects

本发明涉及药物组合物，该药物组合物包含某些氨基甲酸化合物(例如抑制HDAC(组蛋白脱乙酰基酶)活性的)(例如PXD-101、N-羟基-3-(3-苯基氨磺酰基-苯基)-丙烯酰胺))以及一种或多种选自环糊精、精氨酸和葡甲胺的另外的成分。本发明还涉及上述组合物的用途，例如在抑制HDAC中以及在治疗HDAC介导的病症、癌症、增殖性病症、银屑病等疾病中的用途。

USPTO Abstract

本发明涉及药物组合物，该药物组合物包含某些氨基甲酸化合物(例如抑制HDAC(组蛋白脱乙酰基酶)活性的)(例如PXD-101、N-羟基-3-(3-苯基氨磺酰基-苯基)-丙烯酰胺))以及一种或多种选自环糊精、精氨酸和葡甲胺的另外的成分。本发明还涉及上述组合物的用途，例如在抑制HDAC中以及在治疗HDAC介导的病症、癌症、增殖性病症、银屑病等疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN102579417B
Jurisdiction
CN
Classification
—
Expires
2014-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Topotarget UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.